N3-[4-(1H-Imidazol-1-yl)-3-methoxyphenyl]-1-phenyl-1H-1,2,4-triazol-3,5-diamine | 267649-45-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: N3-[4-(1H-Imidazol-1-yl)-3-methoxyphenyl]-1-phenyl-1H-1,2,4-triazol-3,5-diamine
• 英文别名: 3-N-(4-imidazol-1-yl-3-methoxyphenyl)-1-phenyl-1,2,4-triazole-3,5-diamine
• CAS: 267649-45-6
• 化学式: C₁₈H₁₇N₇O
• 分子量: 347.379
• InChiKey: GNNVPNFPRXKJCB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.9
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.06
• 拓扑面积：
  95.8
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• [EN] METABOLISM-MODULATING AGENTS AND USES THEREFOR<br/>[FR] AGENTS DE MODULATION DU MÉTABOLISME ET UTILISATIONS ASSOCIÉES
  申请人：UNIV QUEENSLAND

  公开号：WO2006017896A1

  公开（公告）日：2006-02-23

  The present invention is directed to methods and agents for modulating adipogenesis. More particularly, the present invention relates to molecules that modulate the level or functional activity of inosine-5' monophosphate dehydrogenase (IMPDH) and to their use in modulating the accumulation of lipids in adipocytes and/or the differentiation of preadipocytes to adipocytes for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.

  本发明旨在提供调节脂肪生成的方法和试剂。更具体地，本发明涉及能够调节次黄嘌呤-5'一磷酸脱氢酶（IMPDH）的水平或功能活性的分子，以及它们在调节脂肪细胞中脂质的积累和/或脂肪细胞前体分化为脂肪细胞方面的作用，从而用于治疗或预防与脂肪量相关的疾病，包括但不限于肥胖症、脂肪瘤、脂肪瘤病、恶病质或脂肪营养不良，或由于创伤或萎缩性条件导致的脂肪组织损失。
• METABOLISM-MODULATING AGENTS AND USES THEREFOR
  申请人：THE UNIVERSITY OF QUEENSLAND

  公开号：EP1786415A1

  公开（公告）日：2007-05-23
• Metabolism-modulating agents and uses therefor
  申请人：Whitehead Paul Jonathan

  公开号：US20060106097A1

  公开（公告）日：2006-05-18

  The present invention is directed to methods and agents for modulating adipogenesis. More particularly, the present invention relates to molecules that modulate the level or functional activity of inosine-5′ monophosphate dehydrogenase (IMPDH) and to their use in modulating the accumulation of lipids in adipocytes and/or the differentiation of preadipocytes to adipocytes for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.
• US6399773B1
  申请人：——

  公开号：US6399773B1

  公开（公告）日：2002-06-04
• US7915255B2
  申请人：——

  公开号：US7915255B2

  公开（公告）日：2011-03-29